Option elects Olivier Lefebvre as new Chairman of the Board of Directors
LEUVEN, BELGIUM–(Marketwire – February 22, 2010) -
Composite Technology Announces Line Completion in Belgium
150kV ACCC(R) Conductor Line Installed Between Mol and Beringen
Belgium’s Oscar(R) Contender, "The Misfortunates," to Open at L.A.’s Nuart Theater
LOS ANGELES, CA–(Marketwire – December 7, 2009) – “The Misfortunates,” Belgium’s official
entry for the Motion Picture Academy’s Foreign Language Film category, will
open at the Nuart Theater in West Los Angeles on December 11 for a one week
run. A nationwide release is planned for February 2010. Distributed by
NeoClassics Films, it is also competing for the [...]
Larian Studios Committed to Emergent’s Gamebryo for Developing Diverse Titles, Including the Highly Anticipated Divinity II: Ego Draconis
FLANDERS, BELGIUM–(Marketwire – December 7, 2009) – Larian Studios today named Emergent’s
Gamebryo its development engine of choice, revealing that they have
utilized Emergent’s tech to bring a variety of multi-faceted projects to
life, including the highly anticipated Divinity II: Ego Draconis. This next
installment in the critically acclaimed Divinity series is available now on
PC in Germany and [...]
Galapagos receives EUREKA innovation label and OSEO funding
MECHELEN, BELGIUM–(Marketwire – November 26, 2009) –
Mechelen, Belgium; 26 November 2009 – Galapagos NV (Euronext: GLPG)
announces that its antibody therapeutics program with MorphoSys and
SARM program have been awarded funding by the French governmental
organization OSEO. Accordingly, the Paris-based Galapagos R&D center
will receive interest free loans from OSEO worth [...]
GTM501 HSPA wireless module winner at GSMA’s Embedded Mobile Module competition
LEUVEN, BELGIUM–(Marketwire – November 18, 2009) – Option, the wireless technology
company, today announced that its GTM501, the world’s smallest HSPA
module and one of Option’s broadband wireless breakthroughs, has been
selected as the winner of the GSMA’s Embedded Mobile Module
competition in the [...]
Galapagos initiates Nanocort(R) Phase II clinical trial for multiple sclerosis
MECHELEN, BELGIUM–(Marketwire – November 17, 2009) – Galapagos NV (Euronext: GLPG)
announced today that it has started a Phase II clinical study to
evaluate Nanocort’s effectiveness in treating flares in multiple
sclerosis (MS). Nanocort combines less frequent treatment with lower
dosage and potentially more effective delivery [...]

0 Comments